MedCentralAHA/ACC Issue First-Ever Multi-Society CKM Guidance

✅ Guideline Update

The 2026 AHA/ACC/ADA/ASN guideline formalizes CKM syndrome as a continuum linking obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. It introduces five stages (0 to 4) and replaces the 2013 obesity management guideline with a risk-stratified, interdisciplinary framework designed to guide earlier identification and intervention.

Clinical Considerations

• CKM staging (0-4) standardizes risk identification across obesity, T2D, CKD, and CVD in a single framework
• PREVENT equations are the recommended tool for estimating 10- and 30-year ASCVD, heart failure, and CVD risk in stages 0-3
• SGLT2 inhibitors and GLP-1-based therapies are endorsed based on cardiovascular and renal risk, not glucose control thresholds alone
• Both eGFR and UACR are required to assess CKD status and guide kidney-protective therapy selection
• Routine assessment of social determinants of health is explicitly integrated into CKM management

Practice Applications

• Incorporate CKM staging into routine patient assessment, particularly for those with obesity, T2D, or CKD
• Consider SGLT2 inhibitors and GLP-1-based therapies when cardiovascular or renal risk is elevated, independent of glycemic targets
• Assess waist circumference alongside BMI to identify adiposity as a primary CKM driver
• Monitor UACR routinely in at-risk patients; initiate kidney-protective therapy when albuminuria persists
• Coordinate care across cardiology, nephrology, and endocrinology; consider a designated care coordinator for complex CKM patients